Some examples include enasidenib for mutated isocitrate dehydrogenase 2 (IDH2) and Ivosidenib for mutated isocitrate dehydrogenase 1 (IDH1) in acute myeloid leukaemia (AML), 5-fluorouracil inhibiting Thymidylate synthase in gastric and breast cancer, and Methotrexate inhibiting dihydrofolate reductase (DHFR) in breast and lung cancer (58, 59). Here, IDH1 is linked to acute myeloid leukemia.